Celularity Inc
For the period ended Mar 31, 2025. Filed Aug 29, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed Aug 29, 2025
CELU$0.71-6.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes In Stockholders’ (Deficit) Equity
Condensed Consolidated Statements of Changes In Stockholders’ (Deficit) Equity (Unaudited)
(In thousands, except share amounts)
| Common Stock · Additional Paid—in · Accumulated · Accumulated Other Comprehensive · Total Stockholders’ (Deficit) | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Income (Loss) | Equity | |
| Balances at January 1, 2024 | 19,378,192 | $2 | $882,749 | $(841,791) | $— | $40,960 |
| Issuance of common stock to Yorkville for debt extension and SEPA commitment fee | 116,964 | — | 317 | — | — | 317 |
| Issuance and modification of warrants to RWI and C.V. Starr | — | — | 3,322 | — | — | 3,322 |
| Issuance of common stock and warrants in PIPE Offering, net of offering expenses | 2,141,098 | — | 6,000 | — | — | 6,000 |
| Vesting of restricted stock units | 233,361 | — | — | — | — | — |
| Tax withholding on vesting of restricted stock units | (80,672) | — | (357) | — | — | (357) |
| Issuance of common stock to Palantir as consideration for settlement agreement | 20,000 | — | 50 | — | — | 50 |
| Retirement of shares in connection with reverse stock split | (191) | — | — | — | — | — |
| Stock-based compensation expense | — | — | 2,966 | — | — | 2,966 |
| Net loss | — | — | — | (22,013) | — | (22,013) |
| Balances at March 31, 2024 | 21,808,752 | 2 | 895,047 | (863,804) | — | 31,245 |
| Balances at January 1, 2025 | 22,546,671 | $2 | $908,523 | $(899,683) | $(5) | $8,837 |
| Tax withholding on vesting of restricted stock units | — | — | (98) | — | — | (98) |
| Vesting of restricted stock units | 87,419 | — | — | — | — | — |
| Issuance of common stock to Dragasac in connection with warrant repricing | 1,188,255 | 2,460 | — | — | 2,460 | |
| Dragasac warrant inducement | — | — | 64 | (64) | — | — |
| Issuance of common stock consideration shares to Yorkville in connection with Side Letter | 100,000 | — | 149 | — | — | 149 |
| Issuance of common stock in connection with settlement of debt | 21,739 | — | 51 | — | — | 51 |
| Issuance and modification of warrants to C. V. Starr | — | — | 207 | — | — | 207 |
| Changes in fair value of debt | — | — | — | — | 5 | 5 |
| Stock-based compensation expense | — | — | 2,637 | — | — | 2,637 |
| Net loss | — | — | — | (19,754) | — | (19,754) |
| Balances at March 31, 2025 | 23,944,084 | $2 | $913,993 | $(919,501) | $— | $(5,506) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.